Table 2.
Results among survey respondents (N=57)
| 1. “Study Completers” received all 3 injections (N= 27) |
2. Received 1–2 injections (N=11) |
3. Unsuccessful induction (0 injections) (N= 19) |
P* | |
|---|---|---|---|---|
| Substance Use | ||||
| Any opioid use following parent study | 19 (70.4%) | 9 (81.8%) | 16 (84.2%) | ns |
| Opioid use progressed to daily use | 11 (40.7) | 7 (63.6%) | 16 (84.2%) | 0.012 (1<2=3) |
| • Time to daily opioid use (days) among those reporting any daily use since parent study | 68.8 (+/− 30.7) | 12.4 (+/− 32.4) | 5.5 (+/− 10.7) | <0.001 (1>2=3) |
| Any opioid use in past month of survey | 8 (29.6%) | 4 (36.4%) | 6 (31.6%) | ns |
| • Heroin as primary opioid | 4 (14.8%) | 2 (18.2%) | 6 (31.6%) | ns |
| • Injection drug use | 0 (0%) | 0 (0%) | 4 (21%) | 0.018 (3>1=2) |
| Past month cocaine use | 3 (11.1%) | 0 (0%) | 0 (0%) | ns |
| Past month marijuana use | 7 (25.9%) | 6 (54.5%) | 2 (10.5%) | 0.031 (2>3) |
| Past month alcohol use | 15 (55.6%) | 4 (36.4%) | 4 (21.1%) | 0.033 (1>3) |
| Past month nicotine use | 16 (59.3%) | 6 (54.5%) | 5 (26.3%) | 0.038 (1>3) |
| Overdose (none were fatal) | 1 (4.8%) | 0 (0%) | 1 (5.3%) | ns |
| Treatment Continuation | ||||
| Received XR-NTX after study completion | 13 (48.1%) | 2 (18.2%) | 0 (0%) | 0.001 (1>3) |
| • Number of injections received | 6.5 (+/−3.7) | 3 (+/−2.8) | N/A | ns |
| Active treatment (any, not including AA/NA) | 7 (25.9%) | 5 (45.5%) | 8 (42.1%) | ns |
| • XR-NTX | 6 (22.2%) | 1 (9.1%) | 0 (0%) | 0.002 (1>3) |
| • Buprenorphine | 0 (0%) | 2 (18.2%) | 3 (15.8%) | ns |
| • Methadone | 1 (3.7%) | 1 (9.1%) | 5 (26.3%) | ns |
| • Psychotherapy/groups | 5 (18.5%) | 1 (9.1%) | 6 (31.6%) | ns |
| Attitudes | ||||
| Know someone on XR-NTX (past year) | 11 (40.7%) | 1 (9.1%) | 6 (31.6%) | ns |
| • Reports positive effect | 8 (29.6%) | 1 (9.1%) | 3 (15.8%) | ns |
| Know someone on buprenorphine (past year) | 19 (70.3%) | 6 (54.5%) | 13 (68.4%) | ns |
| • Reports positive effect | 8 (29.6%) | 2 (18.2%) | 9 (47.4%) | ns |
| Would recommend XR-NTX to others (agree/strongly agree) | 24 (88.9%) | 9 (81.2%) | 11 (57.9%) | 0.044 (1>3) |
| Barriers to continuing XR-NTX (among subgroup no longer receiving XR-NTX) | N=21 | N=10 | N=19 | |
| Internal | ||||
| • “Felt cured” | 11 (52.4%) | 2 (20%) | N/A | ns |
| • “Wanted to do it on my own” | 5 (23.8%) | 1 (10%) | N/A | ns |
| Side Effects | 1 (4.8%) | 6 (60%) | N/A | 0.002 (1<2) |
| External | ||||
| • Cost | 4 (19%) | 2 (20%) | N/A | ns |
| • Lacked insurance reimbursement | 3 (14.3%) | 0 (0%) | N/A | ns |